Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Nausea and Vomiting, Postoperative

Treatments: Drug: GW679769 (casopitant)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00326248

NKT102553

Details and patient eligibility

About

This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.

Enrollment: 482 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of PONV and/or motion sickness.
• Have not smoked for the last 6 months.
• Having certain types of abdominal, breast or shoulder surgeries.

Exclusion criteria

• Pregnant or breastfeeding.
• Taking certain medications.
• Have certain pre-existing medical conditions.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

482 participants in 1 patient group

Arm 1

Experimental group

Treatment:

Drug: GW679769 (casopitant)